Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018)

Published:2020-03-12 Issue:5 Volume:30 Page:351-373
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Liu Yi-Min¹²,Kuo Chun-Nan³⁴,Liou Jing-Ping¹³

Affiliation:

1. TMU Biomedical Commercialization Center, Taipei Medical University, Taipei, Taiwan

2. Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

3. School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan

4. Department of Pharmacy, Taipei Medical University, Taipei Municipal Wanfang Hospital, Taipei, Taiwan

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2020.1738389

Reference71 articles.

1. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer

2. Cell Signaling by Receptor Tyrosine Kinases

3. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

4. Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma

5. Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: A patient with ALK-positive large B-cell lymphoma benefited from myeloma-like treatment combined with the ALK inhibitor lorlatinib;Frontiers in Hematology;2024-03-06

2. An updated patent review of anaplastic lymphoma kinase inhibitors (2018–2022);Expert Opinion on Therapeutic Patents;2023-04-03

3. Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs;Pharmaceutics;2022-07-28

4. An update of new small-molecule anticancer drugs approved from 2015 to 2020;European Journal of Medicinal Chemistry;2021-08

5. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015–2020;Bioorganic Chemistry;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3